SAW
NTLA icon

Signal Advisors Wealth’s Intellia Therapeutics NTLA Stock Holding History

Signal Advisors Wealth’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-77,436
Closed -$552K – 520
2025
Q1 		$552K Buy
77,436
+3,278
+4% +$33.1K 0.05% 262
2024
Q4 		$865K Buy
74,158
+27,782
+60% +$434K 0.1% 197
2024
Q3 		$953K Buy
+46,376
New +$1.07M 0.14% 178

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Signal Advisors Wealth's NTLA Position: Q2 2025 in Review

Signal Advisors Wealth sold out of Intellia Therapeutics (NTLA) in Q2 2025, closing a stake of 77,436 shares — an estimated $552K sold.

Signal Advisors Wealth first reported a position in NTLA in Q3 2024 and held it in 3 quarters. The position peaked at $953K in Q3 2024. 280 funds tracked by Wall St. Rank hold NTLA as of Q2 2025.

  • Signal Advisors Wealth reported no remaining Intellia Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Signal Advisors Wealth sold 77,436 Intellia Therapeutics shares in Q2 2025, an estimated $552K.
  • Signal Advisors Wealth first reported a position in Intellia Therapeutics in Q3 2024 and held it in 3 quarters.
  • Signal Advisors Wealth's Intellia Therapeutics position peaked at $953K in Q3 2024.
  • 280 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q2 2025.

Based on Signal Advisors Wealth's 13F filing for Q2 2025, filed 10 Jul 2025.